Shamir Mehta, MD, MSc, FRCPC Director Interventional Cardiology Associate Professor of Medicine McMaster University Hamilton, Ontario, Canada The Balancing.

Slides:



Advertisements
Similar presentations
Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
Advertisements

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Efficacy and Safety.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Major Hemorrhagic Events (Acute Phase) No significant increase in rate of major hemorrhage ESSENCE n = 3171 TIMI 11B n = 3910.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48 Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin.
Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights.
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
Safety and Effectiveness of Bivalirudin in NSTE ACS by duration of the upstream infusion in the ACUITY trial: Implications for ED and upstream management.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Pharmacological strategies to reduce periprocedural bleeding
ACS Management NSTEMI Pro DTI “Hook-ster Hoekstra” Pro Factor Xa “Knockdown Diercks”
BLEEDING AND ACUTE CORONARY SYNDROMES Cardiac Catherization Conference Syed Raza MD Cardiology Fellow VCU Medical Center 06/02/2011.
OASIS 5 Access AHA 2006 Martial Hamon, Shamir Mehta, Gabriel Steg, David Faxon, Prafulla Kerkar, Hans-Jürgen Rupprecht, Jean-Francois Tanguay, Rizwan Afzal,
OASIS in ACS: with Updates on 2011 ESC Guidelines on Anticoagulation Donato Maranon, MD, FPCP, FPCC, FACC.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Steven R. Steinhubl, Frederick Feit, Antonio.
Applications of bivalirudin in interventional cardiology
16th Interventional Cardiology Symposium Montreal, Quebec / June 14-16, 2007 Adapted from a presentation by: Shamir R. Mehta, MD, MSc, FRCPC, FACC “Transitioning.
Compared to Heparin/Enoxaparin with GP IIb/IIa inhibitors,Bivalirudin monotherapy significantly reduces major bleeding while providing similar ischemic.
Switch Switch Safety and Efficacy of Crossover (Switch) from UFH/Enox to Bivalirudin: Results from ACUITY Dr. Harvey White Green Lane Cardiovascular Service.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
STEMI < 6 h Lytic eligible Lytic choice by MD (TNK, tPA, rPA, SK) ENOX < 75 y: 30 mg IV bolus SC 1.0 mg / kg q 12 h (Hosp DC) ≥ 75 y: No bolus SC 0.75.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
TCT Presentation October 2006 Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Enoxaparin in primary PCI From FINESSE to ATOLL G. Montalescot Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France The FINESSE Trial is supported.
Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Intra-procedural Anticoagulation for PCI: Which Drug? How Much? How Long? Michael J. Cowley, FSCAI Nothing to Disclose.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Northeast Georgia Heart Center Interventional Pharmacology: Anti-thrombin Therapy J. Jeffrey Marshall, MD, FSCAI Past President SCAI, Director.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Gregg W. Stone MD for the ACUITY Investigators
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
Antiplatelet Therapy For STEMI: The Case for Cangrelor
Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial Steven.
Seeking the Optimal Upstream Therapy for Patients with ACS: Fondaparinux- Low Bleeding Rate and Low Cost Sanjit S. Jolly MD, Interventional Cardiologist,
Dr. Harvey White on behalf of the ACUITY investigators
The following slides highlight a discussion and analysis of presentations in the Late-Breaking Clinical Trials session from the 55th Annual Scientific.
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
% Heparin + GPI IIb/IIIa Bivalirudin +
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
Importance and Impact of Bleeding on ACS Clinical Outcomes
Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results.
Implications of Preoperative Thienopyridine Use
on behalf of the ACUITY investigators
What oral antiplatelet therapy would you choose?
Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Ron J.G. Peters,
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Baseline Characteristics
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

Shamir Mehta, MD, MSc, FRCPC Director Interventional Cardiology Associate Professor of Medicine McMaster University Hamilton, Ontario, Canada The Balancing Act in ACS Continues – But with Better Outcomes? A Critical Appraisal of Recent Clinical Data

Antithrombotics in UA/NSTEMI Patients in the Last Decade: Increased Efficacy at the Price of Increased Bleeding 16-20% 12-15% 8-12% 6-10% 4-8% Death / MIBleeding 1988 ASA 1992 ASA+ Heparin 1998 ASA+ Heparin+ Anti- GPIIB/IIIA 2003 ASA+ LMWH + Clopidogrel + Intervention

Bleeding is Associated with an Increased 30-Day Mortality in NSTEMI Patients Rao et al. Am J Cardiol 2005;96: N = 26,452 ACS patients from GUSTO IIb, PURSUIT and PARAGON A&B Log-rank p values are for all 4 categories, 0.20 for no bleeding vs. mild bleeding, for mild vs. moderate bleeding, and for moderate vs. severe bleeding. Adjusted HR (95% CI) % Death 2.9% %1.6 ( ) 5.9%2.7 ( ) 25.7%10.6 ( ) GUSTO bleedingNoneMildModerateSevere Days to Death Cumulative survival

Procedure-Related and Non-Procedure-Related Bleeds are Associated with an Increased 30-Day Mortality in NSTEMI Patients Rao et al. Am J Cardiol 2005;96: Procedure-related GUSTO bleeds Non-procedure-related GUSTO bleeds Risk of death (Hazard Ratio) None 1.0 Mild 1.3 Severe None 1.0 Mild 2.1 Moderate 2.5 Severe 10.9 Moderate 3.7 N = 26,452 ACS patients from GUSTO IIb, PURSUIT and PARAGON A & B

OASIS Registry, OASIS-2, CURE Strong, Independent Association Outcome Major Bleed No Major Bleed Hazard (Adjusted) P- Value Death 60/470 (12.8%) 833/33676 (2.5%) 5.37 ( ) < MI 46/436 (10.6%) 1375/33710 (4.1%) 4.44 ( ) < Stroke 12/469 (2.6%) 187/33677 (0.6%) 6.46 ( ) < Eikelboom JW et al. Circulation. 2006;114(8): N = 34,126

Increased Mortality at Days 30/180 in Patients with Major Bleeds by Day 9 (All Patients) Budaj et al. JACC. 2006;abstract Adjusted HR (95% CI) at day 30: 5.06 ( ); at day 180: 3.16 ( ) Major Bleed 9 days No Major Bleed 9 days Cumulative Hazard Days

Increased Risk of MI at Days 30/180 in Patients with Major Bleeds by Day 9 (All Patients) Adjusted HR (95% CI) at day 30: 5.01 ( ); at day 180: 2.99 ( ) Budaj et al. JACC. 2006;abstract Days 0.00 Cumulative Hazard Major Bleed 9 days No Major Bleed 9 days

Increased Risk of Stroke at Days 30/180 in Patients with Major Bleeds by Day 9 (All Patients) Adjusted HR (95% CI) at day 30: 4.77 ( ); at day 180: 3.30 ( ) Budaj et al. JACC. 2006;abstract Cumulative Hazard Days Major Bleed 9 days No Major Bleed 9 days

Potential Mechanisms for the Higher Morbidity/Mortality Associated with Bleeding 1.Activation of clotting cascade as a response to bleeding--may lead to recurrent events in at the site of plaque rupture 2.Cessation of antithrombotic therapies (eg. ASA, clopidogrel, heparin) after a bleeding event 3.Adverse effects of hypotension due to the bleed 4.Adverse effects of transfusion 5.Common risk factors for bleeding and adverse outcome

Coagulation Cascade and New Anticoagulants Rosenberg & Aird. N Engl J Med. 1999;340:1555–64. Wessler & Yin. Thromb Diath Haemorrh. 1974;32:71–8. Inhibition of one molecule of factor Xa can inhibit the generation of 50 molecules of thrombin Intrinsic pathway Extrinsic pathway 1 50 Xa X II Fibrin Fibrinogen Clot Xa Va PL Ca 2+ IIa VIIIa Ca 2+ PL IXa Bivalirudin Fondaparinux

Herbert JM et al. Cardiovasc Drug Rev. 1997;15:1. van Boeckel CAA et al. Angew Chem, Int Ed Engl. 1993;32:1671.  Once daily administration  Rapid onset (C max /2=25 min)  Effects reversible with administration of activated Factor VII (Novoseven®)  No liver metabolism  No protein binding (other than AT)  No risk of pathogen contamination  No reported cases of HIT  No dose adjustment necessary in elderly Fondaparinux: A Synthetic Inhibitor of Factor Xa

IIaII Fibrinogen Fibrin clot Extrinsic pathway Intrinsicpathway AT Xa Fondaparinux Xa Antithrombin Fondaparinux Mechanism of Action Olson et al. J Biol Chem. 1992;267: Turpie et al. N Engl J Med. 2001;344: THROMBIN Recycled

Ephesus N = 1817 Pentathlon 2000 N = 1584 Penthifra N = 1250 Pentamaks N = 724 Overall Odds Reduction % odds reduction Fondaparinux better Enoxaparin better % 28.1% 61.6% 63.1% 55.3% P = Overall odds reduction for proximal DVT = 57.4% [CI: ]; p = Overall Efficacy of Fondaparinux vs Enoxaparin in VTE Prevention: Meta- analysis Turpie et al. Arch Intern Med. 2002;162:

OASIS-5: A Randomized, Double-Blind, Double-Dummy Trial 20,078 patients with UA/NSTEMI Fondaparinux 2.5 mg s.c. od up to 8 days Aspirin, Clopidogrel, anti-GPIIb/IIIa, planned Cath/PCI as per local practice Randomization Enoxaparin 1 mg/kg s.c. bid for 2-8 days 1 mg/kg s.c. od if ClCr<30mL/min Michelangelo OASIS-5 Steering Committee. Am Heart J. 2005;150:1107.e1-.e10. OASIS 5 Investigators. I

Majority of Patients Undergoing Catheterization in OASIS-5 Went Early Mehta et al. JACC 2006; abstract % 17.4% 38.4% <24 hrs24-48 hrs>48 hrs Patients (%) N = 14,206

Similar Efficacy Outcome Rates in Both Groups at Day 9 OASIS-5 Investigators. N Engl J Med. 2006;354: %5.7%Death/MI/RI 1.9% Refractory Ischemia 2.6%2.7%MI 1.8%1.9%Death 4.1% Death/MI FondaparinuxEnoxaparin Non-inferiority Margin = Hazard Ratio Fondaparinux better Enoxaparin better

Major Bleeding: 9 Days Days Cumulative Hazard HR % CI P<< Enoxaparin Fondaparinux

Mortality: Day 30 Days Cumulative Hazard HR % CI P=0.02 Enoxaparin Fondaparinux

Efficacy at 6 Months OASIS 5 Investigators. N Engl J Med. 2006;354: %12.5% Death/MI/Stroke 12.3%13.2%Death/MI/RI 1.3%1.7%Stroke 6.3%6.6%MI 5.8%6.5%Death 10.5%11.4%Death/MI NS P value Fondaparinux betterEnoxaparin better Enoxaparin FondaparinuxHazard Ratio

All Types of Bleeding were Reduced in the Fondaparinux Group at Day 9 OutcomeEnoxaparin (%) Fondaparinux (%) p value No. Randomized10,02110,057 Total bleeds7.33.3<0.001* Major bleeds4.12.1<0.001 TIMI major + fatal bleeds <0.001** Fatal bleeds Minor bleeds3.21.1<0.001 * HR (95% CI): 0.44 ( );**HR (95% CI): 0.55 ( ) OASIS-5 Investigators. N Engl J Med. 2006;354:

The Reduction in Major Bleeding with Fondaparinux was Consistent in Almost All Categories Major bleeding at day 9 Enoxaparin (No. patients) Fondaparinux (No. Patients) p value No. Randomized10,02110,057 Total Major Bleeds412 (4.1%)212 (2.1%)<0.001 Intracranial77NS Requiring surgery7741<0.001 Retroperitoneal379<0.001 Transfusion282160<0.001 Associated with death at study end 7938<0.001 OASIS-5 Investigators. N Engl J Med. 2006;354:

OASIS-5 – The Reduction in Major Bleeding at Day 9 Was Independent of Renal Function OASIS-5 Investigators. N Engl J Med. 2006;354: *88 µmol/L Creatinine 1.9%3.4% <1.04 mg/dL* (n = 8871) 2.4%4.7% >1.04 mg/dL* (n = 11,124) FondaparinuxEnoxaparin Interaction p value = 0.71 Hazard Ratio Fondaparinux betterEnoxaparin better

Major Bleeding was Reduced with Fondaparinux Irrespective of Creatinine Clearance CrCl (mL/min) Enoxaparin* (%) Fondaparinux (%) P value < 30 (n = 535) > 30 (n = 19442) <0.001 OASIS 5 Investigators. N Engl J Med. 2006;354: *Enoxaparin dose reduced to 1 mg/kg od according to label if clearance of creatinine was below 30 mL/min

The Reduction in Major Bleeding at Day 9 with Fondaparinux was Consistent in All Subgroups OASIS-5 Investigators. N Engl J Med 2006;354: Characteristics N Enoxaparin Fondaparinux % Age ≥ 65 yr12, < 65 yr Sex Male12, Female Creatinine At or above median*11, Less than median* Heparin at randomization Yes No16, Revascularization in 9 days Yes No12, < Catheterization laboratory in center Yes 14, No Fondaparinux betterEnoxaparin better * The median value for creatinine was 88 µmol/L (1.04 mg/dL) Interaction p value

Major Bleeding at Day 30 and GP IIb/IIIa Use HR 0.63 P< HR 0.60 P = N = 16448N = 3630

Fondaparinux Superior to Enoxaparin for Bleeding Irrespective of Rx Duration HR 0.69 P = HR 0.55 P < HR 0.67 P = N = 5581N = 8712N = 5785

Incidence of Major Bleeds with Enoxaparin in OASIS-5 is Consistent with Previous Trials EnoxaparinEnoxFondaEnoxFonda SYNERGY 1 In-hospital ESSENCE 2 Day 30 A to Z 3 Day 6 Meta- analysis 4 Day 7 OASIS 5 Day 9 OASIS 5 Day 9 OASIS 5 Day 30 OASIS 5 Day 30 TIMI major+ fatal bleeds 9.1%-0.9%- 1.3%0.7%1.5%1.0% Major bleeds -6.5%-4.7% 4.1%2.2%5.0%3.1% 1.SYNERGY Investigators. JAMA. 2004;292: Cohen et al. N Engl J Med. 337: Blazing et al. JAMA 2004;292: Petersen et al. JAMA. 2004;292:89-96.

Fondaparinux-Associated Reduction of Bleeding Translated into Long-Term Mortality Benefit Patients withEnoxaparinFondaparinuxDifference No Bleed Minor Bleeds Major Bleeds Total No. of deaths at 180 days OASIS-5 Investigators. N Engl J Med. 2006;354:

Days Cumulative Hazard Enoxaparin Fondaparinux HR % CI P<< Net Clinical Benefits at 6 Months (Death, MI, RI, Major Bleeding)

Efficacy and Safety in PCI Patients Outcome Day 9Enox N = 3072 Fonda N = 3105 HR (95% CI)P value Death, MI or Stroke190 (6.2)197 (6.3)1.03 ( ) 0.79 Death38 (1.2)37 (1.2)0.96 ( ) 0.87 MI154 (5.0)160 (5.2)1.03 ( ) 0.80 Stroke13 (0.4)12 (0.4)0.91 ( ) 0.82 Major Bleeding155 (5.1)73 (2.4)0.46 ( ) < Death, MI, stroke, major bleeding 318 (10.4)255 (8.2)0.78 ( ) Mehta et al. JACC. 2006;abstract

PCI < 24 Hours of Randomization Outcome Day 9 Enox N = 1420 Fonda N = 1414 HR (95% CI)P value Death, MI or Stroke77 (5.4)75 (5.3)0.98 ( ) 0.89 Death19 (1.3) 1.01 ( ) 0.98 MI55 (3.9)53 (3.8)0.97 ( ) 0.86 Stroke8 (0.6)6 (0.4)0.76 ( ) 0.60 Major Bleeding69 (4.9)33 (2.3)0.48 ( ) Death, MI, stroke, major bleeding 135 (9.5)103 (7.3)0.76 ( ) Mehta et al. JACC. 2006;abstract 821-5

RR % CI P < RR % CI P = 0.78 RR % CI P < RR % CI P = Major Bleeding 48 hours after PCI Abrupt/threatened abrupt closure N = 1277 N = 1275 N = 1633 N = 1648 N = 1275 RR % CI P=0.62 RR % CI P=0.026 OASIS 5: Fonda vs Enox alone and vs UFH + Enox Mehta et al. Presented at WCC/ESC Hotline Session, Barcelona, % Events Fonda Enox alone UFH + Enox Fonda Enox alone UFH + Enox 1 N = 1633 N = N = 1277 N = 1633 N = 1648 N = 1277 N = 1275

Open Label UFH Prior to PCI Data After Protocol Amendment No UFH Prior to PCIUFH Prior to PCI Enox (%) Fonda (%) HR (95% CI) Enox (%) Fonda (%) HR (95% CI) Number randomized Death/MI/Stroke/Maj or Bleed 90 (11.1)80 (10.1)0.90 ( ) 9 (11.2)4 (5.3)0.45 ( ) Death/MI/Stroke60 (7.4)57 (7.2)0.97 ( ) 5 (6.3)3 (4.0)0.62 ( ) Major Bleed35 (4.3)26 (3.3)0.75 ( ) 5 (6.2)1 (1.3)0.21 ( ) Abrupt Closure13 (1.6)15 (1.9)1.18 ( ) 01 (1.3)-- Threatened abrupt closure 38 (4.7)31 (3.9)0.83 ( ) 2 (2.5)4 (5.3)2.13 ( ) Catheter Thrombus4 (0.5)9 (1.1)2.30 ( ) 01 (1.3)*-- Vascular Access Site complication 56 (6.9)22 (2.8)0.40 ( ) 5 (6.3)1 (1.3)0.21 ( ) Final 1758 patients randomized *represents 1 patient with low dose of UFH 5 IU/kg vs mean dose of 47 IU/kg Mehta et al. JACC. 2006;abstract 821-5

Adding UFH to Fondaparinux is Safe and Preserves the Lower Bleeding with Fondaparinux vs Enoxaparin EnoxFondaHRCI No UFH post- Randomization 1.2 (n = 1277) 0.5 (n = 1313) UFH or equivalent placebo mandated by protocol during PCI 1.1 (n = 1229) 0.4 n = 1279) Open Label UFH2.7 (n = 598) 1.3 (n = 543) Overall1.5 (n = 3104) 0.6 (n = 3135) Yusuf S. et al. N Engl J Med. 2006; 354:2829.

PCI-Related Complications and MACE (death, MI or stroke) HR 0.79 P<< HR 0.81 P< HR 0.75 P<< Mehta et al. JACC 2006;abstract 821-5

Advantage of a Single Dose with Fondaparinux The advantage of a single dose for all patients is clear; in this era of recognition of the common occurrence of medical errors that lead to harm, a single dose would result in fewer medical errors because complex calculations of the type identified in the CRUSADE registry would not be needed Califf. JAMA. 2006;295:

ACUITY Study Design – Patient Flow UFH/Enox + GP IIb/IIIa (N = 4,603) Bivalirudin + GP IIb/IIIa (N = 4,604) Bivalirudin Alone (N = 4,612) R* Moderate-high risk unstable angina or NSTEMI undergoing an invasive strategy GPI upstream (N = 2294) GPI CCL for PCI (N = 2309) GPI upstream (N = 2311) GPI CCL for PCI (N = 2293) Aspirin in all Clopidogrel dosing and timing per local practice Aspirin in all Clopidogrel dosing and timing per local practice *Stratified by pre-angiography thienopyridine use or administration Moderate- high risk ACS Stone GW, et al. N Engl J Med Nov 23;355(21):

ACUITY Primary Outcome: No Difference in Ischemic Outcomes or Major Bleeding with Bivalirudin vs Heparin in Presence of GPI P Sup = 0.93P Sup = 0.39 P Sup = 0.38 Stone GW, et al. N Engl J Med Nov 23;355(21):

ACUITY Primary Endpoint: Lower Bleeding with BIV vs Hep+IIb/IIIa P NI < P Sup = P NI = P Sup = 0.32 P NI < P Sup < Stone GW, et al. N Engl J Med Nov 23;355(21):

ACUITY: Components of the Ischemic Composite UFH/Enoxaparin + GPI vs. Bivalirudin + GPI vs. Bivalirudin Alone P Sup = 0.32P Sup = 0.34P Sup = 0.35P Sup = 0.78 Stone GW, et al. N Engl J Med Nov 23;355(21):

ACUITY: Net Clinical Outcome Composite UFH/Enoxaparin + IIb/IIIa vs. Bivalirudin Alone Men (n = 6444) Women (n = 2771) Diabetes (n = 2585) No diabetes (n = 6630) CrCl ≥60 (n = 6993) CrCl <60 (n = 1644) Age <65 (n = 5051) Age ≥65 (n = 4164) Risk ratio ±95% CI Risk ratio ±95% CI Bival Alone UFH/Enox + IIb/IIIa 7.8% 12.9% US (n = 5224) OUS (n = 3991) 10.6% 9.5% 8.9% 16.1% 10.8% 9.8% 9.5% 11.6% 9.2% 14.7% 11.8% 11.5% 10.4% 16.8% 13.7% 10.9% 13.5% PP int 0.86 ( ) 0.88 ( ) 0.90 ( ) 0.82 ( ) 0.86 ( ) 0.96 ( ) 0.79 ( ) 0.90 ( ) 0.87 ( ) 0.86 ( ) RR (95% CI) Bivalirudin alone better UFH/Enox + IIb/IIIa better Stone GW, et al. N Engl J Med Nov 23;355(21):

ACUITY: Net Clinical Outcome Composite UFH/Enoxaparin + IIb/IIIa vs. Bivalirudin Alone Yes (n = 3197) No (n = 6008) Low (0-2) (n = 1291) Intermed (3-4) (n = 4407) High (5-7) (n = 2449) Elevated (n = 5368) Normal (n = 3841) Risk ratio ±95% CI Risk ratio ±95% CI Bival Alone UFH/Enox + IIb/IIIa 9.2% 11.3% 12.2% 11.1% PP int 0.76 ( ) 1.02 ( ) 12.2% 7.1% 13.3% 9.4% 0.92 ( ) 0.75 ( ) < % 8.6% 13.7% 10.6% 0.96 ( ) 0.81 ( ) Biomarkers (CK/Trop) ST Deviation TIMI Risk Score Pre Thienopyridine 6.4%10.2%0.63 ( ) %10.2%0.92 ( ) %15.2%0.92 ( )0.36 Yes (n = 5192) No (n = 4023) RR (95% CI) Bivalirudin alone better UFH/Enox + IIb/IIIa better Stone GW, et al. N Engl J Med Nov 23;355(21):

ACUITY: Net Clinical Outcome Composite UFH/Enoxaparin + IIb/IIIa vs. Bivalirudin Alone Bivalirudin alone better UFH/Enox + IIb/IIIa better Bival Alone UFH/Enox + IIb/IIIa PP int %13.3%0.87 ( ) %18.2%0.97 ( ) %6.5%0.78 ( ) %9.8%0.85 ( ) %9.4%0.98 ( ) %14.4%0.87 ( ) %10.0%0.91 ( ) %7.1%0.94 ( ) %12.6%0.84 ( )0.21 RR (95% CI) PCI (n = 5170) CABG (n = 1048) Medical (n = 2989) No prior AT (n = 3290) Consistent Rx (n = 5519) Crossover (n = 3211) A-thrombin crossover Early (<3.0 h) Intermediate ( h) Late (≥19.7 h) Risk ratio ±95% CI Risk ratio ±95% CI Actual treatment Rand. to angio/interv. tertiles Stone GW, et al. N Engl J Med Nov 23;355(21):

Summary Fondaparinux reduces bleeding and mortality in patients with NSTEACS compared with enoxaparin including those undergoing early intervention (<24 hours) Standard UFH +/- GPI is recommended in those receiving a PCI Bivalirudin is no different than UFH/enoxaparin in reducing ischemic outcomes or bleeding in presence of a GPI Bivalirudin reduces bleeding compared with UFH/enox + GPI but patients need to be pre-treated with a thienopyridine to maintain efficacy The two agents may be complementary—fondaparinux for initial upstream therapy and bivalirudin in those needing a PCI.